| T cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| T-cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
| Targeting TP53 Mutations in Myelodysplastic Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
| TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
|
Molecular Medicine |
Aplastic Anemia |
| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment |
|
Turkish Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
